Technology
Health
Pharmaceutical

Aclaris Therapeutics

$6.12
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-2.39%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ACRS and other stocks, options, ETFs, and crypto commission-free!

About

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Dermatology Therapeutics and Contract Research segments. Read More The Dermatology Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.

Employees
169
Headquarters
Malvern, Pennsylvania
Founded
2012
Market Cap
252.21M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
393.48K
High Today
$6.25
Low Today
$5.96
Open Price
$6.18
Volume
186.16K
52 Week High
$21.97
52 Week Low
$5.49

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2015 IPO
US

News

Seeking AlphaMar 18

Aclaris Therapeutics (ACRS) CEO Neal Walker on Q4 2018 Results - Earnings Call Transcript

Aclaris Therapeutics (NASDAQ:ACRS) Q4 2018 Earnings Conference Call March 18, 2019 8:00 AM ET Company Participants Kamil Ali-Jackson - Co-Founder and Chief Legal Officer Neal Walker - Co-Founder Chief Executive Officer, President and Director Stuart Shanler - Co-Founder and Chief Scientific Officer Jeff Wayne - Interim Chief Commercial Officer Frank Ruffo - Co-Founder and Chief Financial Officer David Gordon - Chief Medical Officer Conference Call Participants Blair Cohen - Guggenheim Securities T...

0
Simply Wall StMar 1

Should You Worry About Aclaris Therapeutics, Inc.’s (NASDAQ:ACRS) CEO Pay?

Neal Walker became the CEO of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in 2012. First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a snap shot of the business growth. And finally – as a second measure of performance – we will look at the returns shareholders have received over the last few years. The aim of all this is to consider the appropriateness of CEO pay levels. Check out our latest analysis for Aclaris Therapeutics How Does Neal Walke...

255
MarketBeatFeb 26

Stock Price, News, & Analysis for Aclaris Therapeutics

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin t...

19

Earnings

-$1.33
-$1.07
-$0.82
-$0.56
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.99 per share
Actual
-$0.99 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.